Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $4.55M (cash outflow) fell 43.7% year over year, ahead of the -56.6% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -14.3% a year.

Context

  • Accounts receivables amounted to 0.9% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Accounts receivables grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -43.7% holds above the trailing-twelve-month pace of -56.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.55M-240.7% QoQ
Last fiscal yearDec 2025
-$6.37M-70.6% YoY
LTMMar 2026
-$2.84M-56.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.7%——
1 year-70.6%——
3-year CAGR-14.3%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(6.37M) USD
Year-over-year change
+70.6%

Accounts Receivables vs competitors

How AMPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -56.6% is the 5th highest of 7, against a peer median of +64.6%.
  • Accounts receivables amounts to 0.4% of revenue for AMPH, versus a peer median of 0.5%.
AMPH Competitors
Accounts Receivables for AMPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹1.39B INR+110.1%+7.1%0.4%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$212.6M USD+439.5%+15.1%6.8%
VTRSViatris Inc.LTM Jun 2026$76.6M USD-118.0%—0.5%
BHCBausch Health Companies Inc.LTM Jun 2026$73.72M USD+19.1%+33.7%0.7%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD+122.4%—3.4%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$2.84M USD-56.6%-14.3%0.4%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$60K USD-99.4%—0.0%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$0 USD——0.0%
Peer median (excluding AMPH) —+64.6%+15.1%0.5%

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income63.3M91.39M137.55M159.52M98.09M
Depreciation & Amortization26.75M28.74M41.78M57.21M63.2M
Deferred Income Tax4.21M(15.75M)(13.74M)(17.87M)27.63M
Stock-Based Compensation18.69M17.86M20.24M24.37M27.28M
Change in Working Capital(1.92M)(32.18M)(24.21M)(14.55M)(65.97M)
Accounts Receivables(14.92M)(10.13M)(26.09M)(21.67M)(6.37M)
Inventory1.26M(11.75M)(1.72M)(48.8M)(21.06M)
Accounts Payables3.02M(736K)13.24M63.56M(4.56M)
Other Working Capital8.72M(9.56M)(9.64M)(7.64M)(33.98M)
Other Non-Cash Items(13.03M)(878K)21.89M4.71M5.89M
Operating Cash Flow97.99M89.18M183.5M213.39M156.12M
Capital Expenditures(27.46M)(24.03M)(38.17M)(41.04M)(34.88M)
Acquisitions (Net)0421K(506.41M)(129M)0
Purchases of Investments(17.38M)(35.76M)(144.56M)(76.79M)(119.13M)
Sales of Investments18.77M27.97M38.62M126.02M90.29M
Other Investing Activities(2.61M)(1.37M)1.39M(4.12M)(6.61M)
Investing Cash Flow(28.67M)(32.78M)(649.12M)(124.93M)(70.33M)
Debt Repayment32.1M(1.78M)526.34M10.17M5.99M
Common Stock Issued00002.86M
Common Stock Repurchased(28.87M)(39.91M)(58.14M)(85.46M)(75.59M)
Dividends Paid00000
Other Financing Activities(40.24M)15.25M(14.11M)(5.67M)(687K)
Financing Cash Flow(37.02M)(26.44M)454.09M(80.95M)(67.43M)
Effect of Forex Changes(223K)(220K)(282K)(190K)210K
Net Change in Cash32.08M29.75M(11.8M)7.31M18.57M
Free Cash Flow70.54M65.15M145.34M172.35M121.23M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.